COMMUNIQUÉS West-GlobeNewswire

Carbios files its 2023 Universal Registration Document
19/04/2024
Clermont-Ferrand, France, 19 April 2024 (18.30 CEST). Carbios (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastics and [...]
Carbios annonce la mise à disposition de son Document d’enregistrement universel 2023
19/04/2024
Clermont-Ferrand, France, 19 avril 2024 (18h30 CEST). Carbios (Euronext Growth Paris : ALCRB), pionnier dans le développement et l'industrialisation de technologies biologiques pour réinventer le cycle de vie des [...]
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
19/04/2024
HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to [...]
St. Vincent Regional Hospital Verified as Level I Trauma Center by American College of Surgeons
19/04/2024
Billings, Montana, April 19, 2024 (GLOBE NEWSWIRE) -- Intermountain Health St. Vincent Regional Hospital is proud to announce its official verification as a Level I Trauma Center by the American College of Surgeons (ACS [...]
LeMaitre Will Announce First Quarter 2024 Earnings Results May 2, 2024
19/04/2024
BURLINGTON, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2024 financial results on Thursday, May 2, 2024, after the market close [...]
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
19/04/2024
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April [...]
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024
19/04/2024
Company announcement – No. 22 / 2024 Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 Copenhagen, Denmark, April 19, 2024 – Zealand [...]
Dr. Sam Barrell CBE appointed as CEO of LifeArc
19/04/2024
PRESS RELEASE FOR IMMEDIATE PUBLICATION 19 April 2024 Dr. Sam Barrell CBE appointed as CEO of LifeArc LifeArc is pleased to announce the appointment of Dr. Sam Barrell, CBE, as Chief Executive Officer. Sam’s appointment [...]
TScan Therapeutics Announces Closing of Upsized Public Offering
19/04/2024
WALTHAM, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]
ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies for HIV Cure
19/04/2024
Study will enroll participants who initiated treatment shortly after acquiring HIV LOS ANGELES, April 19, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, [...]
PharmAla Closes Private Placement and Concurrent Debt Settlement
19/04/2024
VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, [...]
Lifeward Announces the Appointment of Mike Swinford to its Board of Directors
19/04/2024
Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 19, 2024 ( [...]
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath
19/04/2024
BERKELEY HEIGHTS, N.J., April 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and [...]
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023
19/04/2024
The Company Concluded the Year With Revenue Doubling, Alongside Substantial Improvements in Gross Profit Margins and Net Income FORT LAUDERDALE, FL, April 19, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – VPR Brands LP ( [...]
3Daughters Named “Startup of the Year” at BioLabs Philadelphia Investor Day 2024
19/04/2024
MANSFIELD, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- 3Daughters , Inc., a clinical development company fueling evolutionary healthcare for women, was voted the “Startup of Year” by top life science investors and venture [...]
NeuroMetrix Announces Steps Taken to Enhance Shareholder Value
19/04/2024
Joshua S. Horowitz joins Board of Directors At-the-market equity facility terminated WOBURN, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NASDAQ: NURO) today announced two steps to enhance shareholder [...]
Preliminary Results for the Year Ended 31 December 2023
19/04/2024
19 April 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), [...]
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
19/04/2024
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and [...]
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
19/04/2024
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) - - Data presented in a platform session at the [...]

Pages